<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 19, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147249</url>
  </required_header>
  <id_info>
    <org_study_id>EM-0613</org_study_id>
    <nct_id>NCT02147249</nct_id>
  </id_info>
  <brief_title>Cytokines and Chemokines in Erythema Migrans</brief_title>
  <official_title>Inflammatory Proteins, Gene Polymorphisms, and Transcriptome Profiles in Patients With Erythema Migrans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ljubljana School of Medicine,  Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <authority>Slovenia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to characterize the inflammatory proteins, gene
      polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better
      insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that
      could serve as biomarkers of disease activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>inflammatory proteins in erythema migrans patients</measure>
    <time_frame>up to 12 months follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses in serum and if available, skin, of patients during active infection and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gene polymorphisms in erythema migrans patients</measure>
    <time_frame>at enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The expression of disease-relevant genomic variants will be assessed using ImmunoChip.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>transcriptome profiles in erythema migrans patients</measure>
    <time_frame>at 6 month follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will use RNA sequencing of individual immune cell subtypes from patients to determine their transcriptome.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Erythema Migrans</condition>
  <arm_group>
    <arm_group_label>erythema migrans patients treated with antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adult patients with erythema migrans will be treated with oral antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antibiotic treatment</intervention_name>
    <description>Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days</description>
    <arm_group_label>erythema migrans patients treated with antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  erythema migrans in patients &gt; 18 years

        Exclusion Criteria:

          -  pregnancy or lactation

          -  taking antibiotic with antiborrelial activity within 10 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franc Strle, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dasa Stupica, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dasa Stupica, MD,PhD</last_name>
    <phone>+386 1 5222110</phone>
    <email>cerar.dasa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franc Strle, MD, PhD</last_name>
    <phone>+386 1 5222610</phone>
    <email>franc.strle@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Ljubljana, Department of Infectious Diseases</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dasa Stupica, MD,PhD</last_name>
      <phone>+386 1 5222110</phone>
      <email>cerar.dasa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Franc Strle, MD,PhD</last_name>
      <phone>+386 1 522 2610</phone>
      <email>franc.strle@kclj.si</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Franc Strle</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>erythema migrans</keyword>
  <keyword>Lyme borreliosis</keyword>
  <keyword>inflammation</keyword>
  <keyword>outcome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erythema Chronicum Migrans</mesh_term>
    <mesh_term>Glossitis, Benign Migratory</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
